CDK4/6 inhibitors in Breast Cancer Therapy
- Publisher's listprice EUR 180.99
-
75 065 Ft (71 491 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 7 507 Ft off)
- Discounted price 67 559 Ft (64 342 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
75 065 Ft
Availability
Not yet published.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Elsevier Science
- Date of Publication 1 June 2026
- ISBN 9780443446115
- Binding Paperback
- No. of pages330 pages
- Size 235x191 mm
- Weight 450 g
- Language English 0
Categories
Long description:
CDK4/6 inhibitors in Breast Cancer Therapy examines the pivotal role of CDK4/6 inhibition in treating hormone receptor-positive (HR+)/HER2-negative advanced breast cancer. The book highlights FDA-approved applications of these inhibitors alongside endocrine therapy and explores ongoing research into their potential as neoadjuvant treatments. It provides insights into the drug discovery and development of CDK4/6 inhibitors, covering their molecular mechanisms, pharmacology, and clinical applications. The content addresses their use in mono and adjuvant therapies, as well as challenges in targeting, while also discussing market potential and post-marketing safety issues. This book is a valuable resource for researchers and academics, enhancing understanding of CDK4/6 inhibitors' chemistry and therapeutic implications. By presenting detailed information on clinical trials and market formulations, it equips the audience with essential knowledge to navigate the complexities of targeted breast cancer therapies and contributes to advancing research in this critical area.
MoreTable of Contents:
1. CDK4/6 inhibitors: Drug discovery, development and classification
2. CDK4/6 inhibitors: a medicinal chemistry, pharmacology, in-silico and drug delivery perspectives (SAR, LIGAND BINDING, SMALL MOLECULE, LIPINSKI RULE, PHYSICOCHEMICAL PROPERTIES)
3. Molecular mechanism and mechanism of action of CDK4/6 inhibitors
4. CDK4/6 inhibitors: clinical status, patent review and recent updates
5. The neoteric paradigm of the use of CDK4/6 for breast cancer treatment as mono and adjuvant therapy
6. The repurposing era of CDK4/6 in the treatment of various ailments
7. Cytotoxic profile, molecular modelling, cell cycle arrest and apoptotic induction induced by CDK4/6 inhibitors
8. The present-day means and challenges in the targeting of CDK4/6 inhibitors
9. Market potential and post-marketing safety challenges of CDK4/6 inhibitors
10. CDK4/6 inhibitors: future perspectives
Southern Life, Northern City: The History of Albany's Rapp Road Community
11 941 HUF
10 986 HUF
